但是正如诺和诺德所言，司美格鲁肽无论是减肥版还是降糖版都面临激烈竞争。一方面受到礼来替尔泊肽等同类创新药的强势追击，另一方面受到非法仿制药的市场挤压，销售额增速并未如预期般高歌猛进。

BEIJING, July 31 (Xinhua) -- China's manufacturing sector softened slightly in July due to seasonal factors, but underlying growth momentum remained resilient, with emerging industries gaining ...

BEIJING, July 31 (Xinhua) -- China's manufacturing sector softened slightly in July due to seasonal factors, but underlying growth momentum remained resilient, with emerging industries gaining ...

BEIJING, July 31 (Xinhua) -- China's manufacturing sector softened slightly in July due to seasonal factors, but underlying growth momentum remained resilient, with emerging industries gaining ...

减肥药市场的竞争格局正悄然发生变化。刚于一季度超越K药（默沙东PD-1抑制剂）成为“药王”的司美格鲁肽，已初现颓势。 近期，诺和诺德宣布下调2025年展望。公司预计2025年在固定汇率下，全财年销售额增长8%—14%，此前预期增长13%—21%，销售额预期降低主要与公司的司美格鲁肽产品增长预期较低有关。 7月31日，诺和诺德方面在接受北京商报记者采访时表示，公司正通过稳健全面的临床开发项目来探索不 ...

In her view, affordability remains the shared bottleneck for both developed and emerging economies, compounded by gaps in capacity-building, knowledge, and skills. To accelerate green and zero-carbon ...

但市场反应远比财务数据更激烈，诺和诺德当日美股股价跌幅最高24%。更重要的是，投资者不再把它视为GLP-1减肥药的无可争议领跑者。过去一年，诺和诺德股价已累计暴跌逾58%。

Club提要：7月27日，美国总统特朗普在苏格兰会见欧盟委员会主席冯德莱恩，宣布将对欧商品加征15%关税。欧盟的回应则是对美商品实行零关税准入，并与美达成一系列采购与投资协议。